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Background 
Cardiovascular disease (CVD) remains the leading cause of death across the 
spectrum of chronic kidney disease (CKD), including CKD not requiring dialysis, and 
for patients requiring dialysis or kidney transplantation. There is high prevalence of 
‘conventional’ cardiovascular risk factors in patients with CKD such as hypertension, 
dyslipidaemia, diabetes mellitus, smoking, low physical activity/obesity and prior 
cardiovascular events. Many risk factors contribute to the aetiology and pathogenesis 
of CKD or are shared risk factors for CKD progression[1]. Furthermore, there are 
contributors to accelerated CVD specific to, or exaggerated in CKD. Examples include 
left ventricular hypertrophy (LVH), fluid and electrolyte shifts, proteinuria, functional 
vitamin D deficiency, hyperphosphataemia, chronic inflammation, vascular stiffness 
and/or vascular calcification. There are multiple other putative mechanisms for 
accelerated CVD in CKD patients, identified by phenotyping using state of the art 
imaging, physiological studies and molecular biology, although these are yet to 
translate to clinical practice. This NDT Digest will discuss current clinical evidence for 
addressing CVD risk in CKD.  
 
Personalised CVD risk reduction in CKD patients  
To have maximum acceptability, strategies to reduce CVD risk should be tailored to 
the individual. Interventions targeting CVD risk reduction should be specific to CKD 
stage or renal replacement therapy modality.  The evidence base for many 
interventions varies by CKD stage.  Not all interventions have a strong evidence base, 
either due to challenges of undertaking large randomised controlled trials (RCTs) of 
lifestyle interventions, or due to the lack of specific RCTs in patients with CKD. Non-
pharmacological interventions may include addressing lifestyle such as smoking, 
obesity, salt intake and physical activity. RCTs inform best practice for management 
of dyslipidaemia and blood pressure in CKD to reduce cardiovascular risk[1]. 
 
Optimal treatment of dyslipidaemia in CKD 
The benefits of lowering LDL-cholesterol in with HMG-CoA reductase inhibitors 
(statins) is established in patients without renal dysfunction. Their safety and efficacy 
as secondary and primary CVD prevention in high risk patients is established in large 
RCTs. The overwhelming nature and magnitude of benefits in high risk populations is 
summarized in meta-analyses from the Cholesterol Treatment Triallists 
collaboration[2].  
The SHARP trial clearly demonstrated benefit of lowering LDL-cholesterol with 
simvastatin/ezetimibe compared to placebo as primary prevention of atherosclerotic 
vascular events in patients with CKD not requiring dialysis[3]. By contrast, two large 
RCTs in dialysis patients, 4D and AURORA, showed no demonstrable benefit of statin 
therapy (atorvastatin in 4D, rosuvastatin in AURORA) in dialysis patients[4, 5]. The 
ALERT trial of lipid lowering with fluvastatin to prevent cardiovascular events in renal 
transplant recipients showed that statin therapy was associated with a reduction in 
non-fatal myocardial infarction and cardiac deaths[6].   
The combined weight of these trials in patients with varying degrees of CKD have led 
meta-analyses studying the effect of lipid lowering with statins and/or lowering of LDL-
cholesterol.  The most comprehensive of these meta-analyses from 28 trials in patients 
with various degrees of renal impairment[7] gives  the overall message that lowering 
of LDL-cholesterol has a beneficial effect on prevention of major atherosclerotic 
vascular events in CKD patients not requiring dialysis (including renal transplant 
recipients). As eGFR declines, there is a trend towards smaller relative risk reductions 
for major coronary events and strokes. There appears to be little benefit derived from 
commencing lipid lowering in patients once they start dialysis treatment.  
 
Targeting blood pressure to reduce CVD risk – SPRINT into action? 
Leaving aside that treatment of hypertension is a therapeutic goal in reducing risk of 
CKD progression, it is well established that hypertension is a major modifiable global 
risk factor for reducing risk of CVD. Until recently most guidelines including Kidney 
Disease Improving Global Outcomes (KDIGO) in 2012 recommended aiming for target 
systolic blood pressure (BP) of <140mmHg and <130mmHg with preferential use of 
renin angiotensin system inhibition in the presence of significant proteinuria. However, 
recent compelling data from the 2646 non-dialysis CKD patients in the SPRINT trial 
suggests that there is additional mortality benefit in reduction of systolic BP to 
<120mmHg compared to 140mmHg[8]. Although this was a large trial, the overall 
difference in number of patients experiencing an event between the intervention 
groups was small, with more adverse events in the intensive BP group. Further studies 
would be useful to inform whether targeting this lower blood pressure achieves greater 
benefits on CVD risk in CKD without an excess of adverse events such as falls or 
acute kidney injury.  
In dialysis patients, defining an optimum BP is challenging. Whilst there is clear 
epidemiological evidence that extremes of BP are associated with increased CVD risk, 
it is less clear that reduction in BP with any specific strategy such as medication or 
alterations to ultrafiltration regimens, is associated with consistent definitive benefit. 
Interestingly, a meta-analysis of trials of antihypertensive therapy in dialysis patients 
did show benefit with intervention, although it should be noted that the many patients 
in this analysis did not actually have hypertension per se [9].   
 Sodium and CVD risk  
The data on the association between salt (or sodium) intake and cardiovascular risk 
is controversial. Recent data suggests that in patients with hypertension, excretion of 
>7g/day of sodium, as a marker of salt intake, is associated with increased risk of 
CVD. Excretion of <3g/day was also associated with increased CVD risk[10]. CKD 
populations tend towards hypertension and fluid retention, and these data suggest that 
in many patients with CKD, reduction of sodium intake is likely to be beneficial for 
reducing CVD risk, especially in the setting of most Western diets where sodium 
consumption is high. 
 
The future of CVD risk management of CKD 
Several treatment strategies which might have specific benefits in CKD patient are 
currently being tested in clinical trials. Further refinement of algorithms addressing 
CKD mineral-bone disease is required following the EVOLVE trial with cinacalcet and 
various recently reported trials with vitamin D analogues. Ongoing trials include 
vitamin K supplementation, which may reduce vascular calcification (NCT01742273), 
mineralocorticoid receptor antagonism which may target LVH non-atherosclerotic 
CVD deaths (NCT01848639) and. Until these trials report and are digested, a 
suggested approach to primary prevention of CVD in CKD is shown in Figure 1.  
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Figure 1. Issues to address for primary prevention of CVD in CKD. Abbreviations: 
GFR- glomerular filtration rate, BP-blood pressure, ACR- urinary albumin:creatinine 
ratio, RASi- renin angiotensin system inhibition 
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